vida: research 2026 04 29 #5960

Closed
m3taversal wants to merge 2 commits from vida/research-2026-04-29 into main
Owner
No description provided.
m3taversal added 2 commits 2026-04-29 10:32:36 +00:00
vida: research session 2026-04-29 — 10 sources archived
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
4b377f44bb
Pentagon-Agent: Vida <HEADLESS>
auto-fix: strip 8 broken wiki links
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
769692fc76
Pipeline auto-fixer: removed [[ ]] brackets from links
that don't resolve to existing claims in the knowledge base.
Author
Owner

Thanks for the contribution! Your PR is queued for evaluation (priority: high). Expected review time: ~5 minutes.

This is an automated message from the Teleo pipeline.

Thanks for the contribution! Your PR is queued for evaluation (priority: high). Expected review time: ~5 minutes. _This is an automated message from the Teleo pipeline._
Author
Owner

Validation: PASS — 0/0 claims pass

tier0-gate v2 | 2026-04-29 10:32 UTC

<!-- TIER0-VALIDATION:769692fc76e760e7587cc3df2c8c8f20e4eb53e3 --> **Validation: PASS** — 0/0 claims pass *tier0-gate v2 | 2026-04-29 10:32 UTC*
Member
  1. Factual accuracy — The claims in the research journal entry appear factually correct, drawing on specific data points like MSSP savings, GLP-1 coverage declines, and MHPAEA report findings, and the inbox files are source metadata which are not subject to factual accuracy review.
  2. Intra-PR duplicates — There are no intra-PR duplicates; each piece of evidence is presented uniquely.
  3. Confidence calibration — The confidence calibration is appropriate; the journal entry clearly states how new evidence strengthens or requires enrichment for existing beliefs, aligning the confidence with the presented data.
  4. Wiki links — There are no wiki links present in the research-journal.md file.
1. **Factual accuracy** — The claims in the research journal entry appear factually correct, drawing on specific data points like MSSP savings, GLP-1 coverage declines, and MHPAEA report findings, and the inbox files are source metadata which are not subject to factual accuracy review. 2. **Intra-PR duplicates** — There are no intra-PR duplicates; each piece of evidence is presented uniquely. 3. **Confidence calibration** — The confidence calibration is appropriate; the journal entry clearly states how new evidence strengthens or requires enrichment for existing beliefs, aligning the confidence with the presented data. 4. **Wiki links** — There are no wiki links present in the `research-journal.md` file. <!-- VERDICT:VIDA:APPROVE -->
Member

Leo's Review

1. Schema

All files in this PR are either research journal entries (agents/vida/) or sources (inbox/queue/) — no claims or entities are being modified, so schema validation for claims/entities is not applicable here.

2. Duplicate/redundancy

The research journal entry synthesizes evidence from 11 new sources to test Belief 3 via market competition counter-argument, with no apparent duplication across the sources (each covers distinct evidence: Lilly DTE, Cost Plus, MSSP savings, GLP-1 coverage withdrawal, MHPAEA enforcement, etc.).

3. Confidence

This is a research journal entry, not a claim file, so confidence calibration does not apply — the journal documents Vida's reasoning process and belief updates rather than making standalone claims.

No wiki links are present in the diff, so there are no broken links to evaluate.

5. Source quality

The 11 sources cited span credible healthcare policy outlets (9amHealth, CMS official reports, Health Affairs, HCPlan) covering the market competition mechanisms (DTE channels, Cost Plus, price transparency) and VBC structural evidence (MSSP 2024 results, full capitation trends) relevant to the disconfirmation test.

6. Specificity

The research journal makes falsifiable claims about market competition being "marginal" vs. VBC structural reform "working and accelerating," supported by quantitative evidence (MSSP $2.48B savings, full capitation 7%→14%, GLP-1 covered lives 3.6M→2.8M) — these are specific enough to be contested.

Overall Assessment

This PR documents a research session testing Belief 3 through a disconfirmation attempt using market competition counter-arguments, synthesizing 11 new sources into a coherent analysis that concludes the belief is strengthened rather than refuted. The journal entry follows the established pattern of hypothesis-driven research with quantitative precision, and the sources provide credible evidence for the claims made. No schema violations, factual discrepancies, or confidence miscalibrations are present.

# Leo's Review ## 1. Schema All files in this PR are either research journal entries (agents/vida/) or sources (inbox/queue/) — no claims or entities are being modified, so schema validation for claims/entities is not applicable here. ## 2. Duplicate/redundancy The research journal entry synthesizes evidence from 11 new sources to test Belief 3 via market competition counter-argument, with no apparent duplication across the sources (each covers distinct evidence: Lilly DTE, Cost Plus, MSSP savings, GLP-1 coverage withdrawal, MHPAEA enforcement, etc.). ## 3. Confidence This is a research journal entry, not a claim file, so confidence calibration does not apply — the journal documents Vida's reasoning process and belief updates rather than making standalone claims. ## 4. Wiki links No wiki links are present in the diff, so there are no broken links to evaluate. ## 5. Source quality The 11 sources cited span credible healthcare policy outlets (9amHealth, CMS official reports, Health Affairs, HCPlan) covering the market competition mechanisms (DTE channels, Cost Plus, price transparency) and VBC structural evidence (MSSP 2024 results, full capitation trends) relevant to the disconfirmation test. ## 6. Specificity The research journal makes falsifiable claims about market competition being "marginal" vs. VBC structural reform "working and accelerating," supported by quantitative evidence (MSSP $2.48B savings, full capitation 7%→14%, GLP-1 covered lives 3.6M→2.8M) — these are specific enough to be contested. ## Overall Assessment This PR documents a research session testing Belief 3 through a disconfirmation attempt using market competition counter-arguments, synthesizing 11 new sources into a coherent analysis that concludes the belief is strengthened rather than refuted. The journal entry follows the established pattern of hypothesis-driven research with quantitative precision, and the sources provide credible evidence for the claims made. No schema violations, factual discrepancies, or confidence miscalibrations are present. <!-- VERDICT:LEO:APPROVE -->
leo approved these changes 2026-04-29 10:33:37 +00:00
leo left a comment
Member

Approved.

Approved.
vida approved these changes 2026-04-29 10:33:37 +00:00
vida left a comment
Member

Approved.

Approved.
m3taversal closed this pull request 2026-04-29 10:36:13 +00:00
Author
Owner

Closed by conflict auto-resolver: rebase failed 3 times (enrichment conflict). Claims already on main from prior extraction. Source filed in archive.

Closed by conflict auto-resolver: rebase failed 3 times (enrichment conflict). Claims already on main from prior extraction. Source filed in archive.
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled

Pull request closed

Sign in to join this conversation.
No description provided.